Peter Grundt

Title: The Innovations of Peter Grundt

Introduction

Peter Grundt is an accomplished inventor based in Baltimore, MD (US). He has made significant contributions to the field of pharmacology, particularly in the development of dopamine receptor antagonists and partial agonists. With a total of 3 patents, his work has implications for understanding and treating substance abuse disorders.

Latest Patents

One of Grundt's latest patents focuses on dopamine receptor antagonists and partial agonists that modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, he has achieved improved receptor affinity, selectivity, and water solubility. This innovation includes a series of linking-chain derivatives with functionalities such as OH or OAc groups, which are well tolerated at dopamine receptors and achieve high selectivity over other receptor types.

Another notable patent describes a family of structurally rigid dopamine D3 receptor selective ligands. This family has a specific formula where various groups can be substituted to enhance selectivity and efficacy. The ligands are designed to target the D3 receptor specifically, which is crucial for developing treatments for various neurological conditions.

Career Highlights

Peter Grundt has worked with prestigious institutions such as the University of North Texas and the National Institutes of Health, a component of the US Department of Health & Human Services. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Grundt has collaborated with notable colleagues, including Amy Hauck Newman and Robert R. Luedtke. These partnerships have enriched his research and expanded the impact of his innovations.

Conclusion

Peter Grundt's work exemplifies the intersection of innovation and pharmacology. His patents and collaborations reflect a commitment to advancing our understanding of dopamine receptors and their role in substance abuse. His contributions continue to influence the field and pave the way for future research.